跳至主要内容
临床试验/NCT00666341
NCT00666341已完成2 期

A Double-blind Placebo-controlled Dose-response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma

Allergopharma GmbH & Co. KG1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
50
试验地点
1
主要终点
Systemic reaction (according to Tryba)

研究概览

简要总结

Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen (Phleum pratense)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled asthma against grass pollen allergens
  • positive SPT
  • positive EAST
  • positive specific provocation test

排除标准

  • serious chronic diseases
  • other perennial allergies

研究组 & 干预措施

40 μg rPhleum Immunotherapy

Experimental

Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)

干预措施: rPhleum (Biological)

Placebo

Placebo Comparator

Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.

干预措施: placebo (Drug)

20 μg rPhleum Immunotherapy

Experimental

Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)

干预措施: rPhleum (Biological)

80 μg rPhleum Immunotherapy

Experimental

Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)

干预措施: rPhleum (Biological)

120 μg rPhleum Immunotherapy

Experimental

Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)

干预措施: rPhleum (Biological)

结局指标

主要结局

Systemic reaction (according to Tryba)

时间窗: uptitration phase

Number of patients with at least one systemic reaction (according to Tryba Grade 1-4) with possible, probable or definite relationship to the study medication determined at the end of the uptitration phase.

次要结局

  • Late Phase Reactions(before and at the end of the double-blind phase)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Dose-Response-Study With a Recombinant Cocktail of... | 临床试验